All Things Cardio-Oncology International Cardio-Oncology Society

Dr. Neilan discusses the largest randomized trial in the ICI therapy space, the ATRIUM trial.

Tom Neilan, MD, MPH Director, Cardio-Oncology ProgramCo-Director, Cardiac MR PET CT Program

Learn more about the ATRIUM trial here:https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-04887

Karlis Trusinskis, MD President of IC-OS Latvia chapter speaks about the challenges and opportunities of cardio-oncology care in his country.

Diego Sadler, MD

Section Head Cardio Oncology, Cleveland Clinic Florida

In this episode Dr. Sadler speaks about his pioneering work with the Global Cardio-Oncology Registry. This is the first in kind registry that aims to enroll cardio-oncology patients from around the world. GCOR is a multinational, multicenter prospective observational cohort registry and will collect clinical, laboratory, imaging, demographic and socioeconomic data to identify risk factors associated with increased incidence of cancer therapy related cardiovascular disease.

Dr. Anju Nohria is the Director of the Cardio-Oncology Program at Dana-Farber Brigham Cancer Center and a cardiovascular medicine specialist at Brigham and Women’s Hospital (BWH). In addition, she is an Assistant Professor of Medicine at Harvard Medical School (HMS).

On this episode she discusses the challenges and opportunities of starting a new clinic focused on cardio-oncology care.

Renato Lopes, MD, PhD, FACC

Renato Delascio Lopes

Professor of Medicine

Duke University, School of Medicine

Professor of Medicine Divisions of Internal Medicine and Cardiology, Federal University of Sao Paulo, Sao Paulo, Brazil

Dr. Lopes discusses his ongoing efforts to develop, produce, and distribute cardio-oncology education in Brazil and the United States.  

Dr Vivek Narayan is an Assistant Professor of Medicine at Hospital of the University of Pennsylvania, Philadelphia, US.



View the entire webinar here:
https://www.radcliffecardiology.com/video-index/renal-cell-carcinoma-and-vegf-tki-cardiovascular-toxicity